Sucampo Pharmaceuticals has acquired rare disease company Vtesse for $200 million. The deal provides Sucampo with VTS-270, which is in a pivotal study for the treatment of Niemann-Pick Disease Type C1 (NPC-1) with results expected in mid-2018. Sucampo says it provides the capabilities and resources to accelerate the global development and potential commercialization of VTS-270. Niemann-Pick Disease Type C1 is a rare genetic disorder that begins impacting the lives of those affected from birth...